Caisse DE Depot ET Placement DU Quebec Has $43.41 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caisse DE Depot ET Placement DU Quebec lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 151.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 85,927 shares of the company's stock after purchasing an additional 51,728 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.10% of IDEXX Laboratories worth $43,412,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IDEXX Laboratories by 0.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after buying an additional 2,463 shares during the period. American Century Companies Inc. boosted its position in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after purchasing an additional 177,226 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of IDEXX Laboratories by 13.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock worth $249,855,000 after purchasing an additional 59,519 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in IDEXX Laboratories by 4.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock valued at $205,163,000 after purchasing an additional 15,521 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Piper Sandler restated a "neutral" rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday. They set an "outperform" rating and a $500.00 price target for the company. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $546.56.

IDEXX Laboratories Stock Up 2.1 %

IDXX stock traded up $9.02 during trading hours on Monday, hitting $430.77. The company's stock had a trading volume of 710,969 shares, compared to its average volume of 506,635. The stock has a 50 day moving average price of $451.91 and a two-hundred day moving average price of $477.31. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market capitalization of $35.28 billion, a PE ratio of 41.54, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. During the same period in the prior year, the company posted $2.53 earnings per share. IDEXX Laboratories's revenue for the quarter was up 6.6% on a year-over-year basis. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.